000 | 01436 a2200397 4500 | ||
---|---|---|---|
005 | 20250515030116.0 | ||
264 | 0 | _c20070123 | |
008 | 200701s 0 0 eng d | ||
022 | _a0143-3334 | ||
024 | 7 |
_a10.1093/carcin/bgl071 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aBos, Carina L | |
245 | 0 | 0 |
_aProtein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity. _h[electronic resource] |
260 |
_bCarcinogenesis _cDec 2006 |
||
300 |
_a2371-82 p. _bdigital |
||
500 | _aPublication Type: Journal Article | ||
650 | 0 | 4 |
_aAnti-Inflammatory Agents, Non-Steroidal _xpharmacology |
650 | 0 | 4 | _aCell Line, Tumor |
650 | 0 | 4 |
_aColitis, Ulcerative _xdrug therapy |
650 | 0 | 4 | _aColonic Neoplasms |
650 | 0 | 4 |
_aColorectal Neoplasms _xprevention & control |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aKinetics |
650 | 0 | 4 |
_aMesalamine _xpharmacology |
650 | 0 | 4 |
_aPhosphoprotein Phosphatases _xmetabolism |
650 | 0 | 4 | _aProtein Phosphatase 2 |
650 | 0 | 4 |
_aWnt Proteins _xantagonists & inhibitors |
650 | 0 | 4 |
_abeta Catenin _xantagonists & inhibitors |
700 | 1 | _aDiks, Sander H | |
700 | 1 | _aHardwick, James C H | |
700 | 1 | _aWalburg, Kimberley V | |
700 | 1 | _aPeppelenbosch, Maikel P | |
700 | 1 | _aRichel, Dick J | |
773 | 0 |
_tCarcinogenesis _gvol. 27 _gno. 12 _gp. 2371-82 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1093/carcin/bgl071 _zAvailable from publisher's website |
999 |
_c16325920 _d16325920 |